GAITHERSBURG, Md., March 23 /PRNewswire/ -- MaxCyte, Inc., a clinical stage therapeutic company and pioneer in cell-based therapies, announces Linda Liu, PhD will be a featured speaker at the Keystone Symposia The Potent New Anti-Tumor Immunotherapies meeting on March 28 - April 2, 2007 in Banff, Alberta, Canada.
Dr. Liu’s presentation entitled “Genetically Engineering Cells at Industrial Scale for Immunotherapy” will provide an overview of MaxCyte’s large volume, non viral cell manipulating platform for manufacturing cell based products.
A PDF version of the presentation will be made available on MaxCyte’s website.
About MaxCyte
MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company’s proprietary ex vivo cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.
For more information, visit http://www.maxcyte.com.
This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.
MaxCyte, Inc.
CONTACT: Madhusudan V. Peshwa, PhD, Vice President, Research andDevelopment of MaxCyte, Inc., +1-301-944-1700
Web site: http://www.maxcyte.com//
